These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 14906240)

  • 1. [Neoplasms of cell elements in ascites in cancer and cancerous neoplasms].
    REVUTSKAIA PS
    Dokl Akad Nauk SSSR; 1952 Feb; 82(5):769-72. PubMed ID: 14906240
    [No Abstract]   [Full Text] [Related]  

  • 2. [A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy].
    Hara A; Tsunemi S; Yamamoto M; Izumi N; Iwamoto S
    Gan To Kagaku Ryoho; 2006 Dec; 33(13):2065-7. PubMed ID: 17197755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
    Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
    Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niche-dependent tumorigenic capacity of malignant ovarian ascites-derived cancer cell subpopulations.
    Katz E; Skorecki K; Tzukerman M
    Clin Cancer Res; 2009 Jan; 15(1):70-80. PubMed ID: 19118034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of S-1 combined with weekly Paclitaxel for gastric cancer with cancerous ascites].
    Hara A; Tsunemi S; Yamamoto M; Izumi N; Iwamoto S
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1815-8. PubMed ID: 18030015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice.
    Ajith TA; Anu V; Riji T
    J Exp Ther Oncol; 2008; 7(4):291-8. PubMed ID: 19227009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids.
    Richard C; Matthews D; Duivenvoorden W; Yau J; Wright PS; Th'ng JP
    Clin Cancer Res; 2005 May; 11(9):3523-9. PubMed ID: 15867255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ascites tumors of animals and studies on cancer chemotherapy.
    YOSHIDA T
    J Egypt Med Assoc; 1957; 40(Suppl 7):1-12. PubMed ID: 13525563
    [No Abstract]   [Full Text] [Related]  

  • 9. [Hypersensitivity reaction of highly virulent ascites cancer cells to the antimetabolic effects 2, 4-dinitrophenol].
    WINDISCH F; HEUMANN W; KERNER H
    Z Gesamte Inn Med; 1957 Jan; 12(2):89-90. PubMed ID: 13434225
    [No Abstract]   [Full Text] [Related]  

  • 10. Malignant ascites increases the antioxidant ability of human ovarian (SKOV-3) and gastric adenocarcinoma (KATO-III) cells.
    Yang W; Toffa SE; Lohn JW; Seifalian AM; Winslet MC
    Gynecol Oncol; 2005 Feb; 96(2):430-8. PubMed ID: 15661232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of chemokine receptor and its ligand on migration of ovarian cancer cells].
    Li F; Zhu HS; Han ZQ; Chen G; Gao QL; Jia P; Zhang AL; Xi L; Xu Q; Liao GN; Wang SX; Lu YP; Ma D
    Ai Zheng; 2005 Jan; 24(1):23-7. PubMed ID: 15642195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some aspects of the ascites tumor cell response to a heterologous antiserum.
    ELLEM KA
    Cancer Res; 1958 Nov; 18(10):1179-85. PubMed ID: 13596961
    [No Abstract]   [Full Text] [Related]  

  • 13. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
    Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
    Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ascites tumor development. III. Analysis of an antiserum prepared against the soluble phase of the cell.
    HORN EC
    Growth; 1957 Dec; 21(4):221-37. PubMed ID: 13512752
    [No Abstract]   [Full Text] [Related]  

  • 15. Dissemination of intraperitoneal ovarian cancer: Discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model.
    Feki A; Berardi P; Bellingan G; Major A; Krause KH; Petignat P; Zehra R; Pervaiz S; Irminger-Finger I
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):1-9. PubMed ID: 19179094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
    Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
    Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer.
    Urick ME; Giles JR; Johnson PA
    Gynecol Oncol; 2008 Sep; 110(3):418-24. PubMed ID: 18606441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cancer metabolism & anticancer therapeutics. VIII. Metabolic changes in offsprings of rats treated with cancerous nucleoproteins].
    VALLADARES Y
    Medicina (Madr); 1958; 26(8-9):250-2. PubMed ID: 13589407
    [No Abstract]   [Full Text] [Related]  

  • 20. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles.
    Graves LE; Ariztia EV; Navari JR; Matzel HJ; Stack MS; Fishman DA
    Cancer Res; 2004 Oct; 64(19):7045-9. PubMed ID: 15466198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.